Pfizer and BioNTech have revealed results of an in vitro study that offers additional data on the capability of sera obtained from people who were immunised with their Covid-19 vaccine, BNT162b2, to neutralise the B.1.1.7 lineage (VOC 202012/01).
Gritstone Oncology, a biotech firm developing vaccines, has announced that it is advancing the development of a second generation vaccine against Covid-19.
KSQ Therapeutics has joined forces with Japan-based Takeda Pharmaceutical to research, develop, and commercialise novel immuno-oncology therapies.
Amneal Pharmaceuticals and Kashiv BioSciences announced they have entered into a definitive agreement under which Amneal Pharmaceuticals LLC (“Amneal”), a wholly-owned subsidiary of the Company, will acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“Kashiv Specialty”), a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.
BeiGene announced a collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan.
French drugmaker Sanofi has agreed to acquire clinical-stage biopharmaceutical company Kymab in a deal valued at around $1.45bn.
Celularity, a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and GX Acquisition Corp. (Nasdaq: GXGX), a special purpose acquisition company, today announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp. will combine with Celularity.
Clinical-stage biopharmaceutical company Affinivax has secured $226m in Series C financing to advance the development of new vaccines with its multiple antigen presenting system (MAPS) platform.
German pharmaceutical and life sciences company Bayer has entered into a collaboration and services agreement with biopharmaceutical firm CureVac on Covid-19 vaccine called CVnCoV.
Xencor and The University of Texas MD Anderson Cancer Center announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.